Chapter
Cytogenetic and Molecular Testing Methods
Cytogenetic Findings in CML
Cytogenetic and Molecular Testing
Minimal Residual Disease Monitoring
Chapter V: Molecular Mechanisms in CML Pathogenesis
BCR-ABL Causes Aberrant Signaling in CML
Changes in Telomeres and Telomerases in CML
Genetic Alterations in CML
Pathogenesis of Transformation
Chapter VI: Secondary Resistance to Tyrosine Kinase Inhibitors: Focus on Molecular Mechanisms other than BCR-ABL Overexpression and Mutations
2. Signalling Pathways Included in CML Resistance to TKIs – Towards “BCR-ABLIndependence"
3. Role of Multifunctional (proto-)oncogenes and Tumor Suppressors in CML Resistance to TKIs
4. Programmed Cell Death Capacity of CML Cells –Autophagic Cell Death and Responsiveness to Imatinib (TKIs)
5. Mitochondria and Metabolism in CML Cells
6. Sensitivity of Primitive CD34+ CML Cells to Tyrosine Kinase Inhibitors
Chapter VII: Frontline Therapy
Monitoring Treatment Response
Monitoring for Minimal Residual Disease (MRD)
Improving Treatment Outcomes in the Frontline Setting
TKIs – Fertility and Pregnancy
Chapter VIII: Management of Tyrosine Kinase Inhibitors Resistance
Defining Lack of Response to TKI Therapy and Treatment Failure
Pathophysiology and Causes of Treatment Failure
BCR-ABL Dependent Mechanisms
BCR-ABL-Independent Mechanisms of Resistance
Molecular Monitoring for Resistance
Management of TKI Resistance
Chapter IX: Management of Chronic Myeloid Leukemia (CML): Accelerated Phase(AP)
Accelerated Phase: Diagnostic Criteria
Initial Treatment of Patients in AP
Treatment of Patients with CML in AP with Resistant Disease
Chapter X: Management of Chronic Myeloid Leukemia (CML): Blast Phase (BP)
Chapter XI: Hematopoietic Cell Transplant for CML
Myeloablative (MA) HCT for CML
Indications for HCT for CML in the TKI Era
Chapter XII: Summary of Treatment and Recommended Follow-Up of CML Patients
Agents Approved for First-line Treatment
Agents Approved When First-Line Agent Fails
Chapter XIII: CML in Pediatric Population
Therapy for Pediatric CML
Chapter XIV: Blastic Transformation in Extramedullary Sites
Cases from the Literature 1964-2013
First Sites of Extramedullary Involvement
Chapter XV: Managing CML in Pregnancy
Outcome of Pregnancy Occurring on Tyrosine Kinase Inhibitors
Planning Pregnancy in CML
Treating CML in Pregnancy
Management of the Patient Presenting in Pregnancy
Management of Fertility at Diagnosis
Chapter XVI: Drug and Food Interactions with TKIs
Chapter XVII: Molecular Monitoring of CML: Role for Novel Markers Additional to BCR-ABL
1. Introduction: Why to Search for Additional Prognostic Markers for CML
2. Potential Prognostic/Predictive Markers for CML Patients Additional to BCR-ABL
Novel Approaches to Look for New Predictive/Prognostic Markers
Chapter XVIII: Can We Cure CML without Transplantation?
CML Stem Cells: Can TKIS Alone Cure CML?
Targeting Bcr-Abl for an “Operational Cure” of CML
Targeting CML Stem Cells by Bcr-Abl-Independent and “Synthetic Lethal” Strategies
Chapter XIX: Future Directions